[Efficacy of Saccharomyces boulardii combined with minocycline quadruple therapy for Helicobacter Pylori infection].

Abstract

To assess the efficacy of Saccharomyces boulardii combined with minocycline quadruple therapy in treating patients with Helicobacter pylori (Hp) infection. Data from patients who underwent initial eradication treatment for Hp infection were retrospectively collected from Zhongda Hospital of Southeast University, Liangjiang Hospital of Southeast University, and the Second Affiliated Hospital of Zhejiang University School of Medicine from January 1, 2023 to April 30, 2024. The patients were divided into two groups according to the sterilization regimen: bismuth quadruple group (combined application of vonoprazan, colloidal bismuth pectin, amoxicillin, minocycline), Saccharomyces boulardii group (combined application of vonoprazan, Saccharomyces boulardii, amoxicillin, minocycline). After the breath test was completed, each patient was followed up in the outpatient department of gastroenterology. The rates of Hp eradication [intention-to-treat analysis (ITT) and pre-protocol set (PP) were used to analysed], incidence of adverse eventst were compared between the two groups. A total of 398 patients were included, with 192 patients in the bismuth quadruple group: 100 males and 92 females, aged (46.9±14.5) years; 206 patients in the Saccharomyces boulardii group: 102 males and 104 females, aged (44.1±14.2) years. The median follow-up time [M (Q₁, Q₃)] was 6.9 (6.0, 8.1) weeks. One hundred and eighty-eight patients in the bismuth group and 200 patients in the Saccharomyces boulardii group completed treatment and follow-up, respectively. The TT eradication rate was 93.8% (180/192) and 92.2% (190/206), and the PP eradication rate was 95.7% (180/188) and 95.0% (190/200), respectively, in the bismuth quadruple group and Saccharomyces boulardii group. There were no significant differences (both P>0.05). The overall incidence of adverse events in Saccharomyces boulardii group was lower than that in bismuth quadruple group [20.4% (42/206) vs 51.0% (98/192), (P<0.001)]. The efficacy of Saccharomyces boulardii combined with minocycline quadruple therapy is comparable to that of quadruple therapy, but with fewer adverse events.